2025-12965NoticeWallet

Customs Rules Italian Origin for Pirfenidone Tablets in Import Case

Published Date: 7/11/2025

Notice

Summary

U.S. Customs and Border Protection has officially decided that pirfenidone tablets come from Italy, based on where the main ingredient is made. This affects companies importing these tablets, like Alembic Pharmaceuticals, and could impact trade rules and costs. If anyone wants to challenge this decision, they have until August 11, 2025, to take action.

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Pirfenidone tablets ruled product of Italy

On June 24, 2025, U.S. Customs and Border Protection (CBP) determined that pirfenidone tablets are a product of Italy because the active pharmaceutical ingredient (API) is made in Italy and the processing in India did not substantially transform it. The notice states that Italy is a Trade Agreements Act (TAA)-designated country and India is not, so this finding affects whether the tablets are treated as a designated-country end product for U.S. Government procurement under Buy American/TAA rules. Alembic Pharmaceuticals requested the ruling; any party-at-interest may seek judicial review by August 11, 2025.

Personalized for You

How does this regulation affect your finances?

Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Key Dates

Effective Date
Published Date
6/24/2025
7/11/2025

Department and Agencies

Department
Independent Agency
Agency
Homeland Security Department
U.S. Customs and Border Protection
Source: View HTML

Related Federal Register Documents

Previous / Next Documents

Back to Federal Register